{"id":34964,"date":"2018-02-27T13:15:30","date_gmt":"2018-02-27T12:15:30","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=34964"},"modified":"2018-02-28T10:42:53","modified_gmt":"2018-02-28T09:42:53","slug":"aifa-farmaci-oltre-1-mld-disavanzo-spesa-gennaio-ottobre","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/aifa-farmaci-oltre-1-mld-disavanzo-spesa-gennaio-ottobre\/","title":{"rendered":"AIFA. Medicines: Over 1 billion spending deficit in January-October"},"content":{"rendered":"<p>Rome, 27 February \u2013 Pharmaceutical spending under agreements and for direct purchases amounted to 14,878.2 million euros, with an absolute difference with respect to the total resources of 14.85% (13,842.2 million) equal to +1,036 million, corresponding to a percentage incidence on the National Health Fund of 15.96%. This deficit is calculated by excluding from the pharmaceutical expenditure the estimate of the resources allocated with the funds for innovative oncological and non-oncological medicines. And what emerges from the Aifa monitoring on the <a href=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2015\/06\/soldi.farmci.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-19893 alignright\" src=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2015\/06\/soldi.farmci.jpg\" alt=\"\" width=\"313\" height=\"156\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2015\/06\/soldi.farmci.jpg 698w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2015\/06\/soldi.farmci-300x150.jpg 300w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/a>pharmaceutical expenditure in the period January-October 2017.<\/p>\n<p>Pharmaceutical expenditure for direct purchases amounted to 7,819 million euros, with an incidence on the National Health Fund of 8.39%, equal to a deficit with respect to planned expenditure of 1,396 million. Pharmaceutical expenditure for direct distribution of category A stood at 3,947 million, showing a decrease, compared to the previous year, of 776.9 million (-16.4%).<\/p>\n<p>The trend of pharmaceutical spending paid by the NHS is different which, net of discounts, total sharing (regional tickets and sharing of the reference price) and the pay-back paid to the Regions by pharmaceutical companies, amounted to 6,789 million euros, recording a decrease compared to the previous year of 54 million euros (-0.8%).<\/p>\n<p>In particular, there is a surplus of 360.3 million euro with respect to the planned ceiling for agreed spending. Consumption also decreased, expressed in the number of prescriptions (484 million), equal to -0.6% compared to 2016, while the incidence of the ticket increased by 0.7% (9 million euro). At the same time, an increase of +3.4% in daily doses (+697.6 million) was observed.<\/p>\n<p><a href=\"http:\/\/www.regioni.it\/news\/2018\/02\/27\/farmaci-aifa-oltre-1-mld-disavanzo-spesa-a-gennaio-ottobre-551951\/\" target=\"_blank\" rel=\"noopener\">February 27, 2018 \u2013 Regioni.it<\/a><\/p>\n<p>Related news: <a href=\"http:\/\/www.aifa.gov.it\/sites\/default\/files\/Monitoraggio_Spesa_gennaio-ottobre-2017.pdf\" target=\"_blank\" rel=\"noopener\">AIFA. Monitoring of National and Regional Pharmaceutical Expenditure (January \/ October 2017)\u00a0<\/a><\/p>\n<p class=\"site-block__title\"><a href=\"https:\/\/www.aboutpharma.com\/blog\/2018\/02\/27\/farmaci-senza-obbligo-di-ricetta\/\" target=\"_blank\" rel=\"noopener\">Non-prescription drugs: in 2017 consumption decreased by 4.8%<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Roma, 27 feb &#8211;\u00a0 La spesa farmaceutica convenzionata e per acquisti diretti si \u00e8 attestata a 14.878,2 milioni di euro, con uno scostamento assoluto rispetto alle risorse complessive del 14,85% (13.842,2 milioni) pari a +1.036 milioni, corrispondente ad un\u0019incidenza percentuale sul Fondo sanitario nazionale del 15,96%. Tale disavanzo \u00e8 calcolato avendo escluso dalla spesa farmaceutica &hellip;<\/p>","protected":false},"author":4,"featured_media":4850,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[49,26],"class_list":["post-34964","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-aifa","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=34964"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34964\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/4850"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=34964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=34964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=34964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}